Mesa Laboratories INC /CO/ Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Mark Christopher Capone, a Director of Mesa Laboratories Inc /Co/, received 2,423 shares of common stock on September 9, 2026.
NASDAQ
Shiraz Shabanali Ladiwala, a Director of Mesa Laboratories Inc /Co/, received 2,510 shares of common stock on September 9, 2026.
NASDAQ
Jennifer Sadie Alltoft, a Director of Mesa Laboratories Inc /Co/, received 1,774 shares of common stock on September 9, 2026.
NASDAQ
Shannon Hall, a Director of Mesa Laboratories Inc /Co/, received 1,774 shares of common stock on September 9, 2026.
NASDAQ
John James Sullivan, a Director of Mesa Laboratories Inc /Co/, received 1,774 shares of common stock on September 9, 2026.
NASDAQ
R Tony Tripeny, a Director of Mesa Laboratories Inc /Co/, received 1,774 shares of common stock on September 9, 2026.
NASDAQ
Mark Christopher Capone, a Director of Mesa Laboratories Inc /Co/, reported multiple transactions in common stock on August 15, 2026.
NASDAQ
Jennifer Sadie Alltoft, a Director of Mesa Laboratories Inc /Co/, reported multiple transactions in common stock on August 15, 2026.
NASDAQ
Shiraz Shabanali Ladiwala, a Director of Mesa Laboratories Inc /Co/, reported multiple transactions in common stock on August 15, 2026.
NASDAQ
Shannon Hall, a Director of Mesa Laboratories Inc /Co/, reported multiple transactions in common stock on August 15, 2026.
NASDAQ
R Tony Tripeny, a Director of Mesa Laboratories Inc /Co/, reported multiple transactions in common stock on August 15, 2026.
NASDAQ
John James Sullivan, a Director of Mesa Laboratories Inc /Co/, reported multiple transactions in common stock on August 15, 2026.
NASDAQ
John James Sullivan, a Director of Mesa Laboratories Inc /Co/, sold 7,093 shares of common stock on August 13, 2026 for $112.80 per share.
NASDAQ
Siddhartha Kadia, President and CEO of Mesa Laboratories Inc /Co/, purchased 7,093 shares of common stock on August 13, 2026 for $112.80 per share.
NASDAQ
R Tony Tripeny, a Director of Mesa Laboratories Inc /Co/, purchased 900 shares of common stock on August 13, 2026 for $113.69 per share.
NASDAQ
Mesa Laboratories Inc. reports a Form 4 filing detailing the sale of common stock by SVP Operations Brian Archbold.
NASDAQ
Mesa Laboratories CAO Lyndsey Crennen sold 118 shares of common stock to cover taxes on vested RSUs, with the transaction occurring on June 16, 2026.
NASDAQ
Mesa Laboratories CFO John Sakys sold 1,223 shares of common stock to cover taxes related to RSU vesting, while also reporting indirect beneficial ownership of 50 shares held for his children.
NASDAQ
Brian Archbold, SVP Operations at Mesa Laboratories Inc., reported a transaction involving the sale of common stock and the acquisition of Restricted Stock Units.
NASDAQ
Mesa Laboratories CFO John Sakys reported transactions involving common stock, stock options, and restricted stock units.
NASDAQ
Mesa Laboratories Inc. reports that President and CEO Siddhartha Kadia acquired 35,236 Restricted Stock Units (RSUs) on April 14, 2026.
NASDAQ
Mesa Laboratories Inc. (MLAB) President and CEO Siddhartha Kadia acquired 34,807 Restricted Stock Units (RSUs) on April 14, 2026.
NASDAQ
Mesa Laboratories President and CEO Gary M. Owens reported the forfeiture of 8,211 restricted stock units.
NASDAQ
Mesa Laboratories Director John James Sullivan reported gifting 2,000 shares of common stock to a spousal lifetime access trust.
NASDAQ
Mesa Laboratories President and CEO Gary M Owens acquired 11,558 shares of common stock through the vesting of performance share units.
NASDAQ
A director at Mesa Laboratories reported changes in their beneficial ownership, including the vesting and acquisition of restricted stock units.
NASDAQ
Mesa Laboratories Director John Sullivan reported the vesting of 1,404 restricted stock units and the grant of 2,784 new units, alongside changes in direct and indirect common stock holdings.
NASDAQ
Mesa Laboratories Director Shannon Hall acquired 1,404 shares of common stock through the vesting of restricted stock units and was granted 2,784 new RSUs.
NASDAQ
Mesa Laboratories Director R Tony Tripeny reported the vesting of 1,404 restricted stock units and the grant of 2,784 new units.
NASDAQ
Mesa Laboratories Director Mark Capone saw 1,404 Restricted Stock Units vest and received a new grant of 2,784 RSUs.